We thus speculated that evogliptin, a DPP-4 inhibitor possessing high cardiac tissue distribution profile, may be effective as a disease-modifying agent for CAVD. The gene discussed is DPP4; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.